Results 131 to 140 of about 2,116 (170)
Some of the next articles are maybe not open access.
Tralokinumab for the Treatment of Atopic Dermatitis
American Journal of Clinical Dermatology, 2021Atopic dermatitis (AD) is a relapsing or chronic heterogeneous inflammatory skin disorder with a substantial economic and social impact. AD is a multifactorial disease regulated by a diverse set of environmental and genetic determinants. The main factors involved in the pathogenesis of AD are epidermal barrier dysfunction, immune dysregulation, and ...
Egídio Freitas +2 more
openaire +2 more sources
The tralokinumab story: Nothing is ever simple [PDF]
Journal of Allergy and Clinical Immunology, 2019 Andrea J Apter
exaly +3 more sources
Review of Tralokinumab in the Treatment of Atopic Dermatitis
Annals of Pharmacotherapy, 2022Objective To review pharmacokinetics, efficacy, and safety of tralokinumab in treatment of atopic dermatitis (AD). Data Sources Literature review was conducted using MEDLINE (PubMed), EMBASE, and ClinicalTrials.gov for articles ...
Rohan Singh +4 more
openaire +2 more sources
Tralokinumab for uncontrolled asthma
Expert Opinion on Biological Therapy, 2012Asthma is a chronic inflammatory disease of the airways mainly related to allergen exposure, in which various cytokine-specific pathways interact among themselves to promote IgE hyperproduction, bronchial hyperresponsiveness, eosinophil local recruitment and airways remodeling.
Ileana, Antohe +2 more
openaire +2 more sources
Tralokinumab for the treatment of atopic dermatitis
Prescriber, 2022Tralokinumab (Adtralza) is a new anti‐IL‐13 monoclonal antibody for the treatment of moderate to severe atopic dermatitis. This article summarises its administration, clinical trial efficacy and adverse effects.
openaire +1 more source
Successful treatment of dyshidrotic palmoplantar eczema with tralokinumab
Australasian Journal of DermatologyAbstractDyshidrotic palmoplantar eczema or pompholyx is considered to be a part of the spectrum of atopic dermatitis with a significant impact on the quality of life and limited treatment options. Tralokinumab is a new fully human monoclonal antibody which neutralizes interleukin 13, a chief cytokine in itch pathogenesis and skin barrier defects ...
Nisha V Parmar
exaly +3 more sources
Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes
Journal of Clinical MedicineBackground/Objectives: Tralokinumab, a fully human monoclonal antibody targeting IL-13, has shown efficacy and safety in clinical trials and real-life studies for atopic dermatitis (AD). However, data on its effectiveness across AD phenotypes are limited.
Mario Bruno Guanti, Martina Maurelli
exaly +7 more sources
Corneal Perforation Associated With Tralokinumab
CorneaPurpose: The purpose of this study was to report the first documented case of peripheral corneal perforation associated with tralokinumab therapy for atopic dermatitis. Methods: A detailed clinical examination, imaging, and ...
Javier García-Bardera +6 more
openaire +2 more sources
Safety of tralokinumab for the treatment of atopic dermatitis
British Journal of Dermatology, 2022Abstract Linked Article: Simpson et al. Br J Dermatol 2022; 187:888–899.
openaire +1 more source